MRSA, or methicillin resistant staphylococcus aureus is a bacteria that causes skin infections. It is the scourge of many hospitals and retirement homes because it can be spread by touch contact and is incredibly difficult to treat. As its name implies, it is resistant to methicillin, but many different strains are resistant to all classes of antibiotics:
Aminoglycosides are used to fight infections caused by gram-negative bacteria including e-coli, pseuodomonas.
Carbapenems are broad spectrum antibiotics for gram positive and gram negative bacteria.
Cephalasporins have 5 different sub classes.
Macrolides are used to treat strep, syphillis and respiratory infections.
Penicillins treat a wide range of infections.
Polypeptides treat eye, ear or bladder infections.
Quinolones are used to treat pneumonia, diarrhea and urinary tract infections.
Sulphonamides are used for urinary tract infections
Tetracycline is used to treat acne, syphilis, and chlamydial infections.
Cerexa antibiotics are a new class that are currently in clinical trials. They have shown promise in overcoming the resistance of the MRSA bacteria. They have come through their first two clinical trials with rave reviews. Cerexa Inc. is a subsidiary of Forest Laboratories. You can visit the Cerexa website to learn more about ceftaroline acetate, they drug under investigation.
A full copy of this press release can be found at Eureka Alert.